 |
BIO
Ventures for Global Health
"Lack of market
opportunities for products that address neglected diseases
has made it difficult for some companies to advance innovative
medicines and has kept others out of the field entirely.
To spur industry investment, the developing world opportunities
must be strong enough to compete with other product opportunities
a company faces. Advance Market Commitments do just that.
I applaud the decision by the donors to tackle this problem
head on so we can change the way industry views developing
world markets."
-- Wendy Taylor
Founder, Vice President of Strategy and Operations
BIO
Ventures press release in support of AMC launch
|
 |
The
Bill & Melinda Gates Foundation
The establishment of an Advance Market Commitment (AMC)
for pneumococcal vaccines is an exciting step forward
for global health. The governments of Italy, the U.K.,
Canada, Russia, and Norway have shown great generosity
and leadership in supporting this initiative.
Full
statement of support (PDF - 20K)
|
 |
The Center for American Progress
"The Center for American Progress is proud to endorse
an Advance Market Commitment for a pneumococcal vaccine,
which could prevent the deaths of 5.8 million children
in the years to come. We applaud the United Kingdom, Italy
and Canada for their generous financial commitment. We
call on the Bush Administration and the United States
Congress to add its support, and to take the lead on future
AMCs, such as an AMC for a malaria vaccine."
-- John Podesta
President and CEO |
 |
Center
for Global Development
"Advance market commitments
for vaccines are a smart way to save millions of lives.
I congratulate the donors who are supporting the pneumococcal
disease vaccine advance market pilot for having the courage
and conviction to try something new, for asking themselves
"why not?" and then proceeding to give it a try. I hope
that the international community will be encouraged by
this example to undertake advance market commitments for
other urgently needed vaccines."
-- Ruth Levine
Senior Fellow and Director of Program
Co-Chair, Advance Market Commitments Working Group |
 |
CDV-Mali
"With the data we have
collected, we know that meningitis and pneumonia are big
killers of children in Mali. The principal causes of death
among these children are Hib and pneumococcus. Hib vaccines
have been successful in protecting children. Now with
the AMC funding, this is the time to dramatically improve
the health of our children by protecting them from the
top causes of meningitis and pneumonia with both Hib and
pneumococcal vaccines."
-- Dr. Samba Sow
Coordinator |
 |
Friends of the
Global Fight and the Center
for Global Development
"AMCs are a welcome addition
to the arsenal of weapons in the fight against infectious
diseases. This is an innovative use of market based incentives
to correct the current market failure to create vaccines
for the developing world. I applaud the efforts of the
pharmaceutical companies, public health advocates, and
governments that worked together to bring this launch
to fruition which will hopefully save the lives of millions
around the world, especially women and children."
-- Ed Scott
Chairman and Founder
|
 |
The
Hib Initiative
"We welcome the AMC as a major
advance in the fight for child survival. We at The Hib
Initiative are very excited that children worldwide can
now be protected from the 2 major causes of life-threatening
pneumonia, with both Hib and pneumococcal vaccines."
-- Rana Hajjeh
Project Director |
 |
International
AIDS Vaccine Initiative (IAVI)
"The world urgently
needs better tools to fight infectious diseases, reduce
poverty and improve national and global security. An Advance
Market Commitment is an important component of a suite
of new mechanisms that can stimulate scientific innovation
and speed the delivery of health technologies to millions
of poor people in the developing world."
-- Dr. Robert Hecht
Senior Vice President, Public Policy
IAVI
press release on the AMC launch
|
 |
International Federation of Pharmaceutical Manufacturers
and Associations (IFPMA)
“The IFPMA welcomes the public commitment made by governments
to fund the pilot Advance Market Commitment (AMC) to stimulate
the development of new pneumococcal vaccines. Our research-based
vaccine companies around the world have the necessary
know-how and the AMCs’ innovative financial incentive
can help to encourage them to take on the risk associated
with bringing new vaccines from the laboratory to the
poorest countries that need them.”
-- Dr. Harvey E. Bale
Director General
International Federation of Pharmaceutical Manufacturers
& Associations (IFPMA)
IFPMA
press release in support of AMC launch (PDF- 225K) |
 |
MRC Laboratories, Gambia
"The Gambia
pneumococcal vaccine trial saved thousands of children
from dying of pneumococcal disease. The AMC will save
millions of children of dying of pneumococcal disease."
-- Dr. Richard Adegbola
Head of Bacterial Diseases Program |
 |
Meningitis Research Foundation
"As part of the coalition calling for the rapid introduction
of pneumococcal vaccination in developing countries, Meningitis
Research Foundation welcomes the recommendation for a
pilot Advance Market Commitment (AMC). Pneumococcal disease,
including pneumococcal meningitis is responsible for up
to 1 million deaths in the under fives worldwide, and
many of these deaths could be prevented by immunization."
-- Denise Vaughan
Chief Executive |
 |
Merck and Co., Inc.
"AMCs
are innovative, market-based financing mechanisms that
hold great promise in expanding access to much-needed
vaccines in the developing world. The donors, World Bank
and GAVI deserve important recognition for their significant
efforts in moving AMCs from concept to reality.”
-- Margaret McGlynn
President |
 |
PATH
"Advance Market Commitments will help bring life-saving
vaccines where they are needed most, faster than ever
before, and are a smart investment in our future."
-- Christopher J. Elias, MD, MPH
President
|
 |
GAVIs
PneumoADIP
"The AMC is an innovative approach
to make vaccines available, where they are needed most,
faster than ever before. The pilot AMC for pneumococcal
vaccines will save an estimated 5.8 million lives."
-- Dr. Orin Levine
Executive Director
PneumoADIP
statement of support of AMC launch (PDF - 40K)
|
 |
Sabin
Vaccine Institute
"It gives me great pleasure
to witness what can be achieved with the political will
and scientific expertise that is making an AMC for pneumococcal
vaccines a reality. This is an important health intervention
that will make great strides in eradicating a disease
unduly burdening children in developing countries."
-- Dr. Ciro de Quadros
President & CEO |
 |
The
Vatican
The creative and promising initiative launched today seeks
to counter this trend, since it aims to create "future"
markets for vaccines, primarily those capable of preventing
infant mortality. I assure you of the Holy See's full
support of this humanitarian project, which is inspired
by that spirit of human solidarity which our world needs
in order to overcome every form of selfishness and to
foster the peaceful coexistence of peoples.
-- Pope Benedict XVI
Pope's
Address at Vaccine Project Launch |
 |
Wyeth
"This financial pledge brings much needed attention
to the global burden of pneumococcal disease. We join
the International Federation of Pharmaceutical Manufacturers
and Associations and the global community in commending
the donor countries, and look forward to cooperating
with international partners with the goal of helping
to protect children in developing countries against
the potentially devastating consequences of pneumococcal
disease."
-- Bernard Poussot
President, Chief Operating Officer and Vice Chairman
Wyeth
press release in support of AMCs
Related Information
AMC fact sheets |
